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A bispecific monoclonal antibody against methotrexate and a human
tumour associated antigen augments cytotoxicity of methotrexate-carrier
conjugate
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Summary A bispecific monoclonal antibody, reactive with methotrexate (MTX) and a tumour associated
antigen (gp72) has been produced by fusing spleen cells from MTX immunised mice with 791T/36/3
(anti-gp72) hybridoma. The hybrid antibody was purified from anti-MTX and anti-gp72 antibodies present in
the hybridoma culture supernatant by combinations of affinity chromatography on a MTX-agarose
immunoabsorbent and stepwise acid elution from Sepharose-Protein A. A particular feature of the present
antibody is that it reacts with conjugated MTX; this would allow in vivo targeting of conjugates, increasing
many fold the number of molecules of drug carried or localising to pre-targeted antibody. Dual binding
between tumour cell surface antigen and MTX was demonstrated by the ability of the hybrid antibody to
bridge between tumour cells and MTX as MTX-HSA conjugate, reaction here being detected by flow
cytofluorimetry. Purified hybrid antibody specifically enhanced the in vitro cytotoxicity of MTX-HSA for gp72
positive tumour cells.
The production of monoclonal antibodes reactive with
human tumour-associated antigens has led to interest in their
use for selective delivery of therapeutic agents to tumour sites
(Baldwin et al., 1988). Conventional drugs and toxins such as
ribosomal inhibiting proteins are frequently linked covalently
to antibodies for this purpose. Bispecific antibodies are an
alternative to chemical conjugation, one combining site react-
ing with target antigen and the other with the therapeutic
agent.
The single binding site of each bispecific antibody specific
for the toxic moiety makes the approach initially most attrac-
tive for toxins, where internalisation of only a few molecules
may be needed to produce cytotoxic effects. Such constructs
have been used to target ricin A chain (Webb et al., 1985)
and saporin (Glennie et al., 1988). However, Corvalan et al.
(1987a, b) have used the bispecific approach with a conven-
tional drug, showing that a hybrid antibody to CEA and
vinca alkaloid altered the biodistribution of the drug, and
increased its uptake into tumour xenografts. Treatment with
antibody and drug showed synergistic therapeutic effects,
although anti-tumour effects of the antibody itself may have
contributed significantly to the overall response.
More effective application of bispecific antibodies to con-
ventional drug targeting could be via a carrier to which
multiple drug molecules are linked. In addition to delivering
more drug per antibody molecule, this approach has the
advantage that the toxic and targeting moieties could be
given separately, with better tissue penetration of the smaller
component parts, and the possibility of pre-localisation of
the targeting moiety.
The anti-conjugate specificity of the bispecific antibody
could be for the carrier or the drug. An anti-carrier bispecific
antibody could be used with a range of drugs linked to the
same carrier, but for clinical use, this carrier obviously could
not be a human protein. A carrier for this purpose would
nevertheless require to be poorly immunogenic in humans,
but sufficiently immunogenic in other species to allow pro-
duction of a monoclonal antibody. Alternatively, an anti-
drug specificity could be used, selecting an antibody that
binds to carrier conjugated drug, allowing the use of a
human protein or a non-immunogenic polymer as carrier. In
this case, the binding activity of the antibody to free drug
should not be high in comparison to conjugated drug, to
ensure that free drug released during conjugate metabolism
does not displace conjugate from the targeting moiety.
The last approach has been evaluated in the present study.
A hybrid hybridoma producing bispecific monoclonal
antibody reactive with a gp72 human tumour associated cell
surface antigen and with methotrexate (MTX) preferentially
in the form of methotrexate-human serum albumin conjugate
(MTX-HSA) has been produced. A technique for isolating
the bispecific antibody from the hybridoma culture super-
natant, using an immunoabsorbent of MTX in conjunction
with protein A, has been developed. The ability of the
purified bispecific antibody to bridge between cell surface
tumour antigen and MTX-HSA and its effect on the cytotox-
icity of this conjugate has been assessed.
Materials and methods
Tumour cell lines
Lines of the gp72 positive human osteosarcomas 791T and
788T, bladder carcinoma T24 and colon carcinoma C170
which express only low levels of gp72, and gp72 negative
colon carcinoma Colo-205 were maintained in tissue culture
in Dulbecco's MEM with 10% fetal calf serum or MEM with
10% newborn calf serum. They were harvested with trypsin-
EDTA for use in in vitro assays.
Methotrexate and conjugates
L-Methotrexate (MTX) was obtained from Lederle (Gosport,
Hampshire, UK). MTX conjugated to human serum albumin
(HSA) at molar ratios of 23:1-40:1, prepared by carbo-
diimide coupling of MTX to HSA (Garnett et al., 1983), was
supplied by Dr M.C. Garnett of this department. MTX-
thyroglobulin conjugate prepared by a similar procedure was
a gift from Dr G.W. Aherne (Department of Biochemistry,
University of Surrey, UK).
Immunisation andfusion
Balb/c mice were given two intraperitoneal immunisations
with 50 fig of MTX as HSA conjugate, alum precipitated and
mixed with pertussis vaccine, at monthly intervals, followed
one month later by an injection with alum precipitated
material alone and then after a further two months with
MTX-HSA alone. Four days later, 2 x 107 spleen cells were
fused using polyethylene glycol (PEG 1500, Boehringer
Mannheim, Lewis, Sussex, UK) with 2 x 107 6-thioguanine
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resistant 791T/36/3 hybridoma cells (Embleton et al., 1981)
and the products were plated in two 96-well microtitre plates
in Dulbecco's medium containing 15% fetal calf serum and
HMT. Eighty-eight of the 192 wells seeded following the
initial fusion contained cell growth. Of these, 11 produced
supernatants reactive with both 791T cells and MTX-HSA
but not HSA as screened in ELISA assays in the continued
presence of HMT. The mass culture (516/88) with the highest
titre was selected for cloning and re-cloning. Culture super-
natants of the final hybridoma contained both IgGI and
IgG2b, but not other subclasses. Tests with anti-light chain
antisera detected only kappa reactivity.
Purification ofhybrid antibody
In vitro culture in RPMI medium supplemented with 1%
fetal calf serum and 0.25% Primatone (Bioprocessing, Con-
sett, Co. Durham, UK) was used to produce supernatant for
purification of the hybrid antibody. Two methods of
antibody purification were used:
Method A Supernatant (200- 1,000 ml) freed of cells and
debris by centrifugation was passed through a column
(2 cm x 4cm) of MTX-agarose (2-4mg of MTX ml-' of
gel, Sigma Chemical Company, Dorset, UK) to absorb any
anti-MTX and hybrid antibody, and to leave any anti-gp72
component in the unbound fraction. Antibody bound to the
column was then eluted with either pH 3.0, 0.1 M citrate
buffer or 3 M sodium thiocyanate. The fractions correspond-
ing to the eluted peak of protein were pooled, and dialysed
against pH 7.2 phosphate buffered saline pH 7.2 (PBS). In
five purification runs, the yield of MTX-agarose eluate was
28-35 Ig ml-' of original culture supernatant (mean
30 jLg ml-'). These fractions were found to contain both
IgGl and IgG2b isotypes. These fractions were then applied
to a 1.5 x 7 cm protein A column (Pharmacia, Bucks., UK).
Stepwise elution with pH 6.0 and then pH 3.0, 0.1 M citrate
buffer or 3 M sodium thiocyanate was then carried out, and
the eluted fractions dialysed against PBS. The pH 6 eluate
(putatively anti-MTX antibody) contained only IgGI (mean
yield 16jig ml-'), and the pH 3 or sodium thiocyanate
eluates (putatively hybrid antibody) contained both isotypes
(mean yield 8 jig ml-').
Method B This was designed to isolate anti-gp72 antibody
as well as the bispecific and anti-MTX components. Hy-
bridoma culture supernatant was applied first to the Protein
A column, and elution carried out at pH 6.0 (mean yield
17 jig ml-' of putative anti-MTX antibody) and at pH 3 (to
give a mixture of hybrid and anti-gp72 antibodies). After
dialysis against PBS, protein eluted in the second peak was
applied to the MTX-agarose column giving an unbound
fraction (mean yield 37 jig ml-' of putative anti-gp72 anti-
body) and bound material which was subsequently eluted
with pH 3.0 buffer (mean yield 6jg ml-' of putative hybrid
antibody).
The protein concentrations of purified antibody and
immunoglobulin preparations were determined spectro-
photometrically given that Elcml% is 14.3 Isotype deter-
mination was carried out by radial immunodiffusion assay
with anti-mouse subclass and light chain antiserum (Miles
Laboratories, Bucks., UK). Sodium dodecyl sulphate (SDS)
polyacrylamide gel electrophoresis of purified antibody was
performed with a vertical slab gel composed of a 12.5%
acrylamide separating gel overlaid with a 5% stacking gel.
The material was run in both reduced and non-reduced form
and a range of molecular weight markers was also run to
allow calibration of the gel.
Elisa assaysfor antibody binding activity
Elisa assays were performed essentially as previously de-
scribed (Austin et al., 1990), using wells coated by incubation
overnight at 4°C with 1 jLg per well of MTX-HSA. To
prepare wells with 791T tumour cells, 2 x 104 cells per well
were incubated overnight at 37°C in tissue culture medium,
washed three times in PBS, and then fixed with 50jil of
0.01% glutaraldehyde in PBS. Control wells in which
antibody fractions were replaced with control immuno-
globulins were included in each test and the data presented is
net of the optical density of these wells.
In competition assays, the competing material (MTX,
MTX-HSA or MTX-thyroglobulin) was added to the
antibody preparations before addition to the wells. Inhibition
was quantified as per cent reduction in the ELISA absorb-
ence value compared with equivalent amount of antibody
without competitor.
Analysis ofantibody reaction with tumour cells byflow
cytofluorimetry
To examine the reaction of purified antibody preparations
with cell surface antigens on viable cells, 2 x 105 antigen
positive 791T or antigen negative colo-205 cells were
incubated with 5 jg of the preparations in 0.5 ml of Eagle's
medium containing 2% calf serum for 30min in ice. Cells
were then washed three times with the same medium and
suspended in 0.1 ml of a 1/40 dilution of fluorescein
isothiocyanate (FITC) labelled rabbit anti-mouse Ig
antiserum (Dako Ltd) and incubated for a further 30 min in
ice. The cells were then washed once and resuspended in
0.25 ml of a 1:1 mixture of 1% paraformaldehyde and
Eagle's medium containing 2% calf serum. Positive controls
were cells treated with 791T/36 antibody and negative con-
trols were cells treated with medium alone.
To demonstrate the ability of purified antibody prepara-
tions to react simultaneously with gp72 tumour cell surface
antigen and with MTX-HSA, tumour cells were suspended in
0.5 ml of medium containing 5 jLg of antibody and 4jig of
MTX-HSA conjugate. Subsequently the cells were treated
with 1/40 dilution of FITC labelled rabbit-anti-HSA anti-
HSA antiserum (Dako Ltd). Negative controls here included
cells treated with monoclonal antibodies alone followed by
FITC-anti-HSA. The fluorescence of the cells was quantified
under standardized conditions of analysis (Roe et al., 1985).
Briefly, 200 mW of 488 nm light from an argon laser was
used to excite fluorescence, which was collected via a 10 nm
bandwidth bandpass filter centred at 515 nm. Mean channel
number was determined for distributions containing
2,000-5,000 cells, and taking into account the amplification
used, a mean linear fluorescence value was calculated.
Cytotoxicity assays
Cultured tumour cells were plated in 96-well flat-bottomed
tissue culture microtiter plates (Falcon 3072, Becton Dickin-
son and Co.) at I04 cells in 0.1 ml growth medium
(MEM + 10% newborn calf serum) per well. They were
incubated at 37°C for 4 h to allow attachment, then mono-
clonal antibody diluted in growth medium was added in
0.05 ml per well. Wells not treated with antibody received
0.05 ml growth medium. After a further 30 min incubation,
MTX or HSA-MTX conjugate was added in 0.05 ml
medium, with untreated wells receiving medium alone.
All treatments were carried out in quadruplicate. The
plates were incubated for 24 h, then 0.05 ml medium contain-
ing 0.1 jiCi (37 kBq) 75Se-selenomethionine (Se-Met) was
added to each well. A further overnight incubation (16 h)
was performed, then the supernatant medium was removed
and the cells were carefully washed three times under a
stream of PBS. The plates were dried and sealed with a
plastic spray film (Nobecutane, Astra Chemicals), and the
wells separated by means of a band saw for counting in a
gamma spectrometer.
Per cent cytotoxicity mediated by MTX, MTX-HSA,
monoclonal antibody or any combination was calculated by
comparison with mean cell survival (c.p.m.) in control wells
treated with growth medium only. The significance of devia-
tions from control levels was assessed by the Student's t test.510 M.V. PIMM et al.
Results
Antigen binding characteristics offractions
Using purification method A, fractions isolated from MTX-
agarose and those obtained by their further fractionation by
pH step-wise elution from protein A all reacted against
MTX-HSA. With purification method B, the pH 6 eluate
from protein A reacted with MTX-HSA, while the pH 3
eluate, after further purification on MTX-agarose, gave an
unbound fraction not reactive with MTX-HSA, and an
eluted fraction which was reactive with MTX-HSA (Table I).
Flow cytometry showed that the material eluted at pH 6
from protein A after MTX-agarose purification by method A
(putatively anti-MTX antibody) did not react with 791T cells.
The material eluted at pH 3 (putatively hybrid antibody)
reacted with 791T cells to give mean liner fluorescence values
similar to those seen with the positive control of 791T/36
antibody. These fractions showed no reaction with the
antigen negative Colo-205 cells (Table II). In tests with frac-
tions from method B, the unbound material from MTX-
agarose (putatively anti-gp72 antibody) reacted with 791T
but not Colo-205 cells. The material finally eluted from
MTX-agarose (putatively bispecific antibody) also reacted
with 791T cells but not Colo-205 with fluorescence values
virtually identical to the reaction of 791T/36 antibody.
Dual binding reaction between MTX and tumour cell surface
antigen
Preparations reacting with both MTX-HSA and gp72 antigen
contained antibody capable of bridging between the two
antigens (Table III). For example, with purification method
A, the fractions eluted from protein A at pH 3, in simul-
taneous reaction with 791T cells and MTX-HSA, gave a
MLF value of 307 when cell binding of the MTX-HSA was
detected with FITC labelled anti-HSA, but only 31 against
the antigenically negative Colo-205 cells. Cells treated with
this pH 3 fraction alone and subsequently with FITC labelled
anti-HSA showed no reaction (MLF 19 and 22 with 791T
and Colo-205 cells). The fractions eluted from Protein A at
pH 6 showed no bridging reaction between 791T cells and
MTX-HSA, MLF values being only in the range of 16-23
with or without the presence of the MTX-HSA against either
cell type.
Where the culture supernatant had been fractionated first
on Protein A and then on MTX-agarose (method B), the
bound and eluted fraction from the Protein A showed a
similar bridging reaction (Table III). Cells treated with 791T/
36 antibody, with or without MTX-HSA, or with MTX-HSA
alone, showed no binding of the FITC labelled anti-HSA.
The molecular weight of the purified antibody component
showing dual antigen binding specificity was determined by
Table III Examples of simultaneous reaction of
tumour cells
Table I Examples of antibody reactivity of hybridoma 516 culture
supernatant fractions
Purification ELISA absorbence value
method Fraction elutedfrom against MTX-HSAT
A MTX-agarose pH 3 1.35
Protein A pH 6 1.32
Protein A pH 3 1.49
B Protein A pH 6 0.22
MTX-agarose unbound 0.02
MTX-agarose pH 3 0.23
'AlI fractions were tested at 6 Lgml-'.




Purification Fraction/antibody 791T CoLo2O5
AT Protein A pH 6 47 39
Protein A pH 3 1047 57
791T/36b 1266 54
Bc MTX-agarose unbound 1014 51
MTX-agarose pH 3 577 72
791T/36 602 49
'Antibody had been previously bound to and eluted from
MTX-agarose. b791T/36 - positive control of 791T/36 antibody.
CAntibody had been previously bound to and eluted from protein A.
Each preparation's fractions were tested in a separate assay and
therefore each included a positive control of 791T/36 antibody.
SDS-polyacrylamide gel electrophoresis to be 150,000 Da. On
reduction fragments of the appropriate molecular sizes of
IgG heavy and light chains.
Specificity ofMTX binding ofbispecific antibody
The specificity of MTX binding of bispecific antibody was
examined in competitive ELISA assays. In the first test
(Table IV) in which hybrid antibody was at 100pg ml-', the
addition of 1 g ml-' of MTX as MTX-HSA reduced the
final optical density of the ELISA reaction by 88%, with
almost complete inhibition at higher concentrations. In con-
trast free MTX even at 10tg ml-' only reduced the final
optical density by 54%, and to achieve inhibition similar to
that seen with I jg ml-' of MTX as MTX-HSA the concen-
tration of free drug had to be increased to 100jig ml-'. Free
HSA did not effectively inhibit binding of the hybrid
antibody.
MTX-thyroglobulin also inhibited binding of the hybrid
antibody to MTX-HSA, although not as efficiently as MTX-
HSA. Thus in the second test where MTX-HSA at 5 gg ml-'
of MTX inhibited binding of the hybrid antibody by 99%,
hybrid hybridoma culture supernatant fractions with
,and MTX-HSA
Cells incubated with' MLF" after reaction with
Purification Fraction/ Admixed FITC anti-HSA with cells of
method antibody with 791T CoLo2O5
Ac Protein A-pH 6 MTX-HSA 23 21
18 16
Protein A-pH 3 MTX-HSA 307 31
19 22
Bd MTX-agarose-unbound MTX-HSA 26 28
23 26
MTX-agarose-pH 3 MTX-HSA 194 45
16 18




'Cells were incubated with a mixture of antibody fractions and MTX-HSA washed and bound
MTX-HSA subsequently detected with FITC labelled anti-HSA. bMLF = mean linear fluorescence per cell. CAntibody had been previously bound and eluted from MTX-agarose. "Antibody had been previously
bound and eluted from protein A at pH 3.BISPECIFIC ANTIBODY TO METHOTREXATE AND TUMOUR ANTIGEN
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aConcentration in terms of MTX.
MTX-thyroglobulin at the same MTX concentration
inhibited by only 49%. In the third test, where MTX-
thyroglobulin was again compared with MTX-HSA,
I jig ml-' of MTX as MTX-thyroglobulin inhibited binding
by 55%, compared with 88% with MTX-HSA. In the final
test, the concentration of antibody in the ELISA assay was
decreased to 6 jig ml-' to increase the sensitivity of detection
of inhibition. MTX as MTX-HSA produced virtually total
inhibition of binding at 2.5jigml-' and upwards, whereas
free MTX at 2.5 ig ml-' reduced binding by only 25%.
Increasing the concentration of the free drug up to
00 jig ml-' reduced inhibition of hybrid binding to 70%. In
this test HSA alone, at concentrations equivalent to MTX-
HSA conjugate at up to 100jig ml-' of MTX did not inhibit
the binding of the hybrid antibody.
Cytotoxicity ofMTX and MTX-HSA in combination with
monoclonal antibodies
Osteogenic sarcoma 791T and bladder carcinoma T24 cells
were treated in vitro with the bispecific antibody fraction at a
constant concentration of 3 jLg ml-', and free MTX, titrated
from 100 ng ml-' to 1 ng ml-'. As expected from the binding
characteristics of the anti-methotrexate moiety, the bispecific
antibody did not affect the cytotoxicity of free MTX: 50%
inhibitory concentrations (IC50) of 3.5 and 3.7 ng ml-' MTX
were observed for 791T in the presence and absence of
antibody, respectively, and 1.9 and 1.7 ng ml-' in the case of
T24.
An initial experiment was then performed with MTX-HSA
in which the bispecific antibody was again used at 3 jig ml-'
(Figure 1). The MTX-HSA conjugate alone was slightly more
active against T24 than 791T, reflecting the greater sensitivity
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Figure 1 Titration of MTX-HSA conjugate against osteogenic
sarcoma 791T and bladder carcinoma T24 cells with or without
anti-gp72/anti-MTX bispecific antibody (3pgml-'). (0) 791T
cells plus antibody, (A) 791T cells minus antibody, (U) T24 cells
plus antibody, (0) T24 cells minus antibody. The effect of MTX-
HSA against 791T is enhanced at concentrations in the range
equivalent to 0.1-3pgml-' MTX in the presence of antibody
(P <0.01 to P <0.001). Cytotoxicity of MTX-HSA is greater for
T24 than 791T cells, but is not augmented by the bispecific
antibody.
virtually the same whether or not antibody was present, but
the antibody signficantly enhanced the effect against 791T
cells at concentrations of conjugate below 3 jLg ml-' in terms
of MTX content.
The lack of augmentation at higher conjugate concentra-
tions suggested that the system might be in antigen excess, so
further tests on 791T were conducted with MTX-HSA at a
low (non-toxic) dose of 0.25 jig ml-', and antibody was ti-
trated downwards from 50jig ml-' (Figure 2). The cytotox-
icity of MTX-HSA was markedly increased by addition of
bispecific antibody, the response correlating with antibody
concentration. In contrast, the monospecific anti-MTX
antibody fraction and parental 791T/36 (anti-gp72) did not
induce augmentation of cytotoxicity by MTX-HSA, and
addition of bispecific antibody alone (i.e. without the con-
jugate) did not affect target cell survival.
In order to evaluate the specificity of the effect of the
bispecific antibody, experiments were also carried out with
osteogenic sarcoma 788T, which, like 791T, expresses a high
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Figure 2 Titration of anti-gp72/anti-MTX bispecific antibody
and monospecific anti-gp72 and anti-MTX against 791T cells
together with MTX-HSA (equivalent to 0.25jIg ml ' MTX). (0)
Bispecific antibody plus MTX-HSA, (A) anti-MTX plus MTX-
HSA, (-) anti-gp72 plus MTX-HSA, (0) bispecific antibody
alone. The bispecific antibody promotes significant cytotoxicity in
a concentration-dependent manner against 791T by MTX-HSA
compared with MTX-HSA alone which is inactive at
0.25jigml-' MTX (*P<0.01, **P<0.001). The monospecific
antibodies do not significantly increase cytotoxicity above back-
ground, and the bispecific antibody is inactive in the absence of
MTX-HSA.
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cell), and tumour lines T24 and C170 which express onl
about 5-10% of this gp72 level. These lines were chose
because they have similar growth rates to 791T, and simila
sensitivity to MTX. The results (Figure 3) show that 788'
was highly susceptible to the combined action of MTX-HS1
and bispecific antibody, but T24 and C170 were unaffected a
the concentrations tested. In this experiment MTX-HSA
(0.25 yg ml-') in the absence of antibody produced cytotoy
icities of 3% against 788T and below zero against T24 an
C170. The selective effect of bispecific antibody against 791
and 788T confirms that binding of the anti-gp72 moiety wa
necessary for the mediation of cytotoxicity.
A comparison between free MTX and MTX-HSA wa
carried out using the 788T cell line and bispecific antibody a
a constant concentration of 10 agml-', which was highl
effective with this cell line (Figure 3). As shown in Figure a
the antibody produced no change in the titration of fre
drug, but again enhanced the effect of MTX-HSA at lo'
conjugate concentrations, although there was no difference a
the highest concentrations used. This synergism with th
conjugate but not free MTX at the lower equitoxic dose
correlates with greater binding affinity of the bispecifi
antibody for conjugated drug, and the availability of mor
MTX residues per mole of conjugate compared with the fre
drug (i.e. target cell binding of one residue of MTX in th
conjugate can result in internalisation of many others on th
same molecule).
Discussion
The aim of the present study was to generate a hybri
hybridoma producing bispecific monoclonal antibody reac
tive with gp72 human tumour associated antigen and MT)
in the form of a MTX-HSA conjugate, to isolate th
antibody from hybridoma culture supernatant and t
examine its effect on the cytotoxicity of MTX-HSA.
Bispecific antibodies can be made by chemical conjugatior
the use of heterobifunctional reagents allows production c
bispecific antibodies in high yield (Glennie et al., 1988
although preparation of appropriate antibody fragments ma
be a problem, as with the IgG2b 791T/36 in the curren
study. Alternatively, fusion of two hybridomas or a hybrid
oma with immune spleen cells can be undertaken, with ap
propriate physical (Karawajew et al., 1987) or biochemica
selection of hybrid hybridomas (Webb et al., 1985; Corvala
& Smith, 1987). Once established, hybrid hybridomas ca
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Figure 3 Selectivity of augmentation of MTX-HSA cytotoxicity
by anti-gp72/anti-MTX bispecific antibody. (0) Osteogenic sar-
coma 788T cells, (A) bladder carcinoma T24 cells, (U) colon
carcinoma C170 cells. MTX-HSA was used at 0.25 fig ml- ' MTX
concentration. Cytotoxicity against 788T cells which express high
levels of gp72 is highly significant (P <0.001 at all antibody
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Figure 4 Comparative titrations of MTX and MTX-HSA
against osteogenic sarcoma 788T cells with or without bispecific
antibody (10,tgmlh'). (U) MTX plus antibody, (0) MTX
minus antibody, (0) MTX-HSA plus antibody, (A) MTX-HSA
minus antibody. MTX-HSA is less cytotoxic than MTX, but its
effect is enhanced by bispecific antibody (*P <0.01, **P <0.001)
at the lower conjugate concentrations. Cytotoxicity by MTX is
unaffected by the antibody.
ie theoretical maximum yield of bispecific antibody will be 50%
ne of the total immunoglobulin synthesised, the remainder in
this case being bivalent parent antibodies. It should be ap-
preciated that much lower proportions of bispecific antibody
can be produced as a result of other heavy:light chain re-
associations (Milstein & Cuello, 1984). These considerations
id means that it will always be necessary when using the hybrid-
c- hybridoma technique to develop strategies for purification of
X the bispecific antibody from the other antibodies being pro-
ie duced by the hybridoma. Overall, the yield of hybrid
to antibody from the 516 hybrid hybridoma averaged 8gtgml-'
of culture supernatant, an acceptable yield for monoclonal
n; antibodies produced by in vitro culture. However, the total
Df immunoglobulin recovered was 61 fig ml-', with proportions
), of 60% anti-gp72, 26% anti-MTX and 13% bispecific, indi-
ty cating that considerable non-productive association of heavy
nt and light chains, or preferential association of homologous
d- heavy chains, may be occurring.
p- The definitive demonstration that fractions from the
al purification procedures contained bispecific antibody and not
In simply a mixture of two co-purified antibodies came from the
In flow cytometry assays designed to detect bridging between
e cell surface bound antibody and MTX in the form of MTX-
HSA (Table III). The fractions containing both isotypes and
reactive with both antigens when tested separately, could
react simultaneously with gp72 antigen on 791T cells and
with MTX-HSA.
It was proposed that the bispecific antibody produced
should have highest affinity for MTX conjugated to HSA.
Mice were originally immunised with such a conjugate and
initial screening for antibody was carried out against MTX-
HSA in the continued presence of the free MTX in HMT
medium to encourage selection of those antibodies with
preferential binding to the conjugate. The binding of purified
hybrid antibody to immobilised MTX-HSA was inhibited by
soluble MTX-HSA, but not by HSA, and was poorly
inhibited by an equivalent amount of free MTX (Table IV).
MTX-thyroglobulin also inhibited binding of the bispecific
antibody but only about 50% as efficiently as MTX as
MTX-HSA. Overall the interpretation is that this bispecific
antibody reacts with highest affinity against MTX conjugated
0 to HSA, although it is reacting with the MTX moiety and
not with the HSA moiety.
The higher affinity of the bispecific antibody for con-
jugated MTX compared to free MTX is reflected in the
augmentation of cytotoxicity by MTX-HSA but not the free
drug in vitro (Figure 4). An additional factor is the ability of
target cells to internalise up to 40 MTX molecules on each
molecule of MTX-HSA cross-linked by one MTX residue to
a gp72 antigen site, compared with only a single MTX
molecule in the case of free drug.
zu ,
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Using osteogenic sarcoma 788T as the target cell line, 70%
cytotoxicity was achieved using an antibody concentration of
1.6 Lg ml' and MTX-HSA at a concentration equivalent to
0.25tig ml-' MTX (Figure 3), representing a molar ratio
(MTX:Ig) of about 50:1. Previous studies have shown that
conjugates of anti-gp72 antibody coupled directly to MTX-
HSA by a carbodiimide reaction give similar activity against
this cell line at molar ratios around 30:1 (Garnett et al.,
1983). Thus, the bispecific antibody was almost as efficient as
a targeting vector as the chemically linked monospecific
parental antibody. However, saturation of osteosarcoma
791T cells was apparently not reached by bispecific antibody
even at concentrations up to 50jig ml-' (Figure 2), indicating
low affinity or immunoreactivity of the purified fraction. If
this could be improved, the targeting efficiency might equal
or exceed that of chemically coupled anti-gp72 antibody.
Other studies using bispecific antibodies recognising plant
toxins have also shown cytotoxic activities similar to those
obtained with conventional immunotoxin conjugate. Thus,
Webb et al. (1985) produced a hybridoma with anti-ricin
toxin A chain (RTA) and anti-prostate carcinoma activity,
and showed that it could mediate selective cytotoxicity
against prostate tumour cells using RTA at l0-9 M together
with NH4CI as a potentiator. Glennie et al. (1988) showed
that chemically reconstituted bispecific antibodies recognising
an immunoglobulin idiotype on guinea pig leukaemia cells
and the toxin saporin could increase the toxic effect of
saporin for leukaemia cells by almost 5 log units compared to
the toxin alone.
Further studies with this bispecific antibody will examine
in vivo its ability to localise in gp72 positive human tumour
xenografts, to alter the biodistribution of MTX-HSA and to
bring about selective targeting of this conjugate to tumours.
Earlier studies with covalent conjugates of 791T/36 antibody
and MTX have shown blood survival and site specific
localisation of both antibody and drug moieties of the con-
jugates in xenografts (Pimm et al., 1988) and blood survival
of both moieties and tumour localisation of at least antibody
in primary colo-rectal carcinoma (Ballantyne et al., 1988).
However, the maximum molar ratio of MTX to antibody
feasible with those conjugates, at about 3:1, is viewed as a
limitation to their therapeutic efficacy (Pimm et al., 1988). It
has been shown in the present studies that bispecific antibody
can react with MTX-HSA conjugates with up to 40 MTX
molecules per HSA molecule. It is therefore feasible that each
bispecific antibody molecule deposited in tumour tissue
could, in capturing one such molecule via only one of its
MTX groups, encourage selective localisation of many more
drug molecules than is possible with direct covalent conjuga-
tion of the drug to 791T/36 monoclonal antibody.
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